About CZ BioMed Corp.
Founded in 2009 and Incorporate in 2010 as a Nevada Corporation.
The company’s corporate headquarters is located in Tampa, Florida.
CZ BioMed Corp. is a privately held biotechnology company focusing on the discovery, development and commercialization of a new class of potent, genetically engineered common cold virus RVLYSIS® that selectively kills tumor cells, but not normal cells.
Our mission are rooted in the knowledge that our invention and the products we provide affect the quality of patients’ lives. Since everything we do, no matter how small, impacts the end product, we demand the highest ethical and quality standards, both from ourselves and others.
Our mission drives us to achieve excellence and build quality in absolutely everything we do which lead us to the discovery of a new class of high-tech biological products for the treatment of a wide variety of human cancers.
Calvin Cao: Chairman/CEO/President
Mr. Cao’s is the founder of CZ BioMed Corp. As an inventor, innovator and Bio-Entrepreneur, his strategy and commitment to make CZ Biomed the dominant global company on the discovery and development of a new class of high-tech biological products for the treatment of a wide variety of human cancers.
In 2008, As a chairman and co-founder of Stem Cell Therapy International Corp. He engineered the recent merger of Stem Cell Therapy International and Histostem of South Korea. Histostem, one of the largest fully accredited cord blood banks in the world, with more than 80,000 cord blood units for use in research and treatments. The successful merger has formed one of the first fully merged Pacific Rim stem cell companies and cord blood repositories with a U.S. entity Amstem Corp.
John Zhang, MD., PhD: Chief of Science/Vice President
Dr. Zhang received his M.D. and PhD. degrees in China . He has been working on Virology and Tumor biology for more than ten years. He has a broad background in these fields and expertise in key research areas for this application. He laid the groundwork for the oncolytic virus project by developing effective system to kill broad types of tumors. As a result of these previous experiences, he has more than 50 peer-reviewed publications. In summary, he has a demonstrated record of successful and productive research projects in an area of high relevance for oncolytic virus field, and his expertise and experience have prepared us to lead the ongoing project.
Lixian Jiang, Ph.D: Chief Operating Officer/ Vice President
Dr. Lixian (John) Jiang, is a senior Attorney from China and a Patent Agent in the US . He specializes in intellectual property law, China tax law and corporate law. He has worked in a number top specialty law firms. In addition, Dr Jiang is a stem cell scientist. He graduated from University of South Florida Medical School with a PhD degree. He has published approximately 60 original medical articles and abstracts.
Dr. Ronald E. Wheeler, M.D. : Medical Director / Scientific and Medical Advisory Board
A Practicing Urologist for more than 20 years, Dr. Wheeler has focused on male related health issues including impotency and Prostate Diseases associated with BPH, Prostatitis, and Prostate Cancer. He has been a member of the American Urologic Association since 1985 and is a member of the National Institute of Health(NIH) Prostatitis Collaborative.
He is currently Medical Director of the Diagnostic Center for Disease located in Sarasota, FL and of the Prostate Cancer Prevention Foundation.
Dr. Wheeler’s other professional highlights include:
Dr. William Brown Ph.D., J.D., MBA – General and Intellectual Property Lawyer
Responsible for IP due diligence, validity, infringement, patentability, and freedom-to-operate issues (2005-present).
Dr. Kenneth Forster Ph.D. – Medical Advisory Board Member
- Associate Member
- Medical Physicist
- Department of Radiation Oncology
- Moffitt Cancer Center and Research Institute
We model our business after a case study by Harvard Business Review on March 2008 (Harvard Business Review Article). In this model, Choruspharma was a drug development biotech company setup by Eli Lilly as an experiment in 2002.
We believe we can transform the traditional biologics of drug development process through a lean approach for generating clinical proof of concept data and a 100% outsourcing model.
We now have 8 products in our clinical pipeline:
- LURVLYSIS for the treatment of Lung Cancer
- BRVLYSIS for the treatment of Breast Cancer
- PRORVLYSIS for the treatment of Prostate Cancer
- CORVLYSIS for the treatment of Colon Cancer
- CERVLYSIS for the treatment of Cervical Cancer
- MERVLYSIS for the treatment of Melanoma Cancer
- HERVLYSIS for the treatment of Liver Cancer
- OVARVLYSIS for the treatment of Ovarian Cancer
Please contact us for licensing and partnerships.